Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy

Summary

AMP-011 is a Phase 1 study designed to extend the understanding of the toxicity and pharmacology of imexon by investigating a schedule of daily treatment for 5 days every three weeks. The objective of the study is to determine the maximally tolerated dose, the pharmacokinetics, and the toxicity of the drug on the designated schedule.

Timeline

Start

2005-11

Primary completion

2006-09

Completion

2006-10

Drugs

Indications